Travere Therapeutics (TVTX) 3rd Annual Guggenheim Healthcare Innovation Conference summary

Commercial performance

• FILSPARI reached nearly 2,000 new patients in Q3 and generated $200 million in net revenue, supported by strong conversion to paid prescriptions and broad payer access.

• FSGS uptake was broad across primary, genetic and secondary disease, and across nephrologists; management sees no direct competitor in the near term.

• Q3 IgAN seasonality matched prior summers; Q4 prescribing began strongly, with physicians increasingly choosing approved therapies over prolonged ACE inhibitor, SGLT2 or steroid use.

• FILSPARI was the first branded therapy for 90% of patients prescribed it this year; broad payer access continued, without observed pushback on combination therapy.

IgAN treatment landscape

• Updated KDIGO guidance emphasizes complete proteinuria remission and eGFR stabilization; management expects combination treatment to become common as physicians gain experience sequencing therapies.

• Earlier diagnosis may expand the treated population; nephrologists are reportedly more willing to biopsy younger patients with IgAN profiles, while treatment is becoming more aggressive.

• FILSPARI can replace an ACE inhibitor or ARB, which management said may reduce pill burden; IgAN patients average five therapies.

Pipeline and development plans

• Pegtibatinase’s HARMONY Phase III study is enrolling on timeline, with pivotal top-line data expected in H2 next year; the addressable U.S. population under ongoing physician care is estimated at 3,500.

• Classical HCU can cause severe homocysteine-related outcomes; fewer than ~40% of patients are vitamin B6 responders, and existing management can require a strict protein-restricted diet.

• Civorebrutinib IND filing is planned by year-end, followed by U.S. population PK/PD bridging and dosing work; primary membranous nephropathy is the first intended indication, with immune-mediated FSGS and minimal change disease also planned.

• Primary membranous nephropathy affects an estimated 90,000 patients broadly; 60%–70% present with nephrotic syndrome, and current immune-targeted treatments can take a long time to work.